{"id":836692,"date":"2025-04-11T16:10:17","date_gmt":"2025-04-11T20:10:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/"},"modified":"2025-04-11T16:10:17","modified_gmt":"2025-04-11T20:10:17","slug":"organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/","title":{"rendered":"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness"},"content":{"rendered":"<h2>\nOrganogenesis recommends CMS also implement an integrated coverage and payment policy<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">CANTON, Mass., April  11, 2025  (GLOBE NEWSWIRE) &#8212; Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare &amp; Medicaid Services\u2019 (CMS) decision to delay the local coverage determinations (LCDs) for skin substitute grafts\/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to review its coverage policies.<\/p>\n<p align=\"justify\">\u201cOrganogenesis supports an evidence-based approach to coverage and is pleased that CMS has delayed LCD implementation to review its coverage policies to ensure that patients have access to products with \u201chigh quality evidence of effectiveness\u201d, which we believe includes real-world evidence,\u201d said Gary S. Gillheeney, Sr., President, Chief Executive Officer, and Chair of the Board of Organogenesis. \u201cReal-world evidence not only demonstrates a product\u2019s safety and efficacy, but also outcomes in actual clinical use.\u201d<\/p>\n<p align=\"justify\">Gillheeney continued, \u201cAlthough we believe this is an important first step for the industry, we believe coverage policies alone are not sufficient to address rapidly escalating Medicare costs while ensuring cost-effective patient care and innovation. To that end, we recommend CMS implement an integrated coverage and payment policy. As a leader in the space, we will continue to bring stakeholders together to develop and advocate for such an integrated policy that will ensure patient access to the most appropriate products while achieving significant savings to Medicare.\u201d<\/p>\n<p align=\"justify\">Organogenesis has been a leader in regenerative medicine for four decades, innovating and manufacturing a diverse portfolio of highly effective advanced wound care therapies. The Company is a pioneer in bioengineered living cell products, creating the skin substitutes and CTP category in the chronic wound space. Organogenesis has multiple technology platforms supporting clinically proven safe and effective solutions that substantially improve outcomes while lowering the overall cost of care.<\/p>\n<p align=\"justify\">\n        <strong>About Organogenesis Holdings Inc.\u00a0<\/strong><br \/>\n        <br \/>Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=voFwIYQdKZFSU2vwwtcgsOdJ-G7c7gKLZJ4ThFy4je_KgBs-3EpnByNAmCV3PkjXJIV8AJgs-qYGkfx6mxqu0Hv0BFK5H4MjoxrXJc9ReOA=\" rel=\"nofollow\" target=\"_blank\">www.organogenesis.com<\/a>.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWM4NmIyNjYtYmY2Mi00ZWZiLWJhODktY2E4MGYxNDUxZDdkLTExMTA5NzktMjAyNS0wNC0xMS1lbg==\/tiny\/Organogenesis-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Inquiries:\r\nICR Healthcare\r\nMike Piccinino, CFA\r\nOrganoIR@icrinc.com\r\n\r\nPress and Media Inquiries:\r\nOrganogenesis\r\ncommunications@organo.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Organogenesis recommends CMS also implement an integrated coverage and payment policy CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) &#8212; Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare &amp; Medicaid Services\u2019 (CMS) decision to delay the local coverage determinations (LCDs) for skin substitute grafts\/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to review its coverage policies. \u201cOrganogenesis supports an evidence-based approach to coverage and is pleased that CMS has delayed LCD implementation to review its coverage policies to ensure that patients have &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-836692","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Organogenesis recommends CMS also implement an integrated coverage and payment policy CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) &#8212; Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare &amp; Medicaid Services\u2019 (CMS) decision to delay the local coverage determinations (LCDs) for skin substitute grafts\/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to review its coverage policies. \u201cOrganogenesis supports an evidence-based approach to coverage and is pleased that CMS has delayed LCD implementation to review its coverage policies to ensure that patients have &hellip; Continue reading &quot;Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-11T20:10:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness\",\"datePublished\":\"2025-04-11T20:10:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/\"},\"wordCount\":404,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/\",\"name\":\"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=\",\"datePublished\":\"2025-04-11T20:10:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/","og_locale":"en_US","og_type":"article","og_title":"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness - Market Newsdesk","og_description":"Organogenesis recommends CMS also implement an integrated coverage and payment policy CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) &#8212; Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare &amp; Medicaid Services\u2019 (CMS) decision to delay the local coverage determinations (LCDs) for skin substitute grafts\/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to review its coverage policies. \u201cOrganogenesis supports an evidence-based approach to coverage and is pleased that CMS has delayed LCD implementation to review its coverage policies to ensure that patients have &hellip; Continue reading \"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-11T20:10:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness","datePublished":"2025-04-11T20:10:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/"},"wordCount":404,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/","name":"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=","datePublished":"2025-04-11T20:10:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMTMwNCM2ODYzNDgzIzIwOTk0MDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/organogenesis-supports-cms-local-coverage-determination-implementation-delay-to-review-coverage-policies-to-maintain-patient-access-with-high-quality-evidence-of-effectiveness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Organogenesis Supports CMS\u2019 Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=836692"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836692\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=836692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=836692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=836692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}